We use cookies to improve our service and to tailor our content and advertising to you. More infoClose You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our cookies policyClose

Bayer Healthcare Pharmaceuticals has agreed to spend $20m (£14m; €15.6m) to correct misleading direct to consumer advertising of its birth control pill Yaz (drospirenone and ethinylestradiol), the most popular birth control pill in the United States, with sales of about $616m last year.

The corrective advertisements began running last month and will continue through June, the US Food and Drug Administration (FDA) said.

Bayer reached an agreement with the FDA and 27 state attorneys general, led by Bill McCollum, the Florida attorney general. The agreement follows a warning letter sent to Bayer in October by Thomas Abrams, the director of the FDA’s division of drug marketing, advertising, and communications. It adds new requirements to a 2007 agreement about problems related to Bayer’s non-disclosure of safety risks associated …